If you’ve just had the email that your plan will stop paying for Wegovy or Zepbound for weight loss, you’re probably feeling two things at once: a jolt about the cost, and a worry about the months of progress you’ve put in. Both are fair. The good news is you have more than one way through this, and the deadline attached to the letter is usually enough time to make a considered choice rather than a panicked one.
This article is general information, not medical advice. It doesn’t tell you which medication or dose to use, and nothing here is a reason to start, stop, or change a medication on your own. Any decision about your treatment is one for you and your prescriber. For questions about your specific plan, contact your insurer or benefits administrator.
Let’s ground this in the case that put it on everyone’s radar. In June 2026, Cigna told its own workforce, about 67,700 people, that from 1 July it would stop covering GLP-1 medications prescribed for weight loss. Coverage for the same drugs prescribed for type 2 diabetes stayed in place. Current users could refill through the end of June. It’s a notable example because Cigna is itself a large insurer, but it isn’t an isolated one: GoodRx figures reported by NPR put roughly 12 million people on plans that dropped Zepbound and a similar number on plans that dropped Wegovy for weight loss between 2025 and 2026. If your coverage changed, you’re in a very large group.
What “weight-loss coverage dropped, diabetes coverage kept” actually means
This distinction trips people up, so it’s worth being plain about it. The medication in the vial hasn’t changed. Semaglutide is semaglutide whether the prescription says obesity or diabetes. What’s changed is the reason your plan is willing to pay for it. Many employers have decided that GLP-1s for type 2 diabetes stay covered, while the same drug for weight management does not.
For you, that has a few practical consequences. If you’re taking a GLP-1 purely for weight loss, your plan is now treating it as something you pay for yourself. If you happen to have another qualifying condition, your prescriber may look at whether a different, still-covered indication genuinely applies to you. That’s a clinical judgment for them to make honestly, not a box to tick to get around a benefit rule. Don’t ask a prescriber to write a diagnosis you don’t have; do ask them to review your full picture, because plenty of people on these drugs for weight also have conditions worth a proper look.
The other consequence is timing. Most benefit changes come with a last-refill date. Knowing yours is the single most useful thing you can do this week, because it sets how much runway you have.
Your real options, laid out straight
There are four routes people take. None of them is the obvious winner for everyone, so it’s worth knowing what each one actually involves before you pick.
Pay cash. This used to mean the eye-watering list price. It doesn’t have to anymore. Both major manufacturers now run direct-pay programmes for people without coverage, and cash prices at pharmacies have come down as competition and self-pay demand have grown. The number you’ll pay depends on the drug, the dose, and where you fill it, so it’s worth getting an actual quote rather than assuming it’s out of reach. Cash-pay also keeps you on the exact medication you’re already on, which is the simplest thing for your body and your tracking.
Switch to an oral GLP-1. Oral options have expanded, and for some people a daily tablet is both cheaper and easier than injections. It’s not a like-for-like swap — the drug, the dose schedule, and often the strength of effect differ — so it’s a genuine change to plan with your prescriber, not a downgrade you can assume is equivalent. But if cost is the deciding factor, it’s a real lever, and the daily rhythm suits some people better than a weekly shot.
Look at a compounded route — carefully. Compounded semaglutide is made by a pharmacy rather than a manufacturer, and it is not an FDA-approved product. That’s not a scare line, it’s just the category it sits in, and it matters for what you’re getting. The regulatory ground here is moving: the FDA has proposed excluding semaglutide and tirzepatide from the drugs that 503B outsourcing facilities can compound in bulk, and the public comment window on that proposal closed on 29 June 2026. A final rule could narrow access further. Individual-prescription (503A) pharmacies are a separate category and manufacturers are challenging that path in court too. If you’re considering this route, the honest advice is to ask your prescriber and pharmacy what’s genuinely available to you right now, and to be clear-eyed that it may not stay available.
Drop to a maintenance dose. If you’re already at or near your goal weight, you may not need the full dose you were titrating toward. Some people stay on a lower maintenance dose that costs less and holds their result. Whether that’s right for you — and what “maintenance” looks like on your specific medication — is a prescriber conversation, but it’s an option worth raising if cost is the pressure and you’ve mostly arrived where you wanted to be. We’ve written more about holding your weight after you hit your goal.
Notice what these have in common: every one runs through your prescriber. That’s not a disclaimer for its own sake. A dose change, a drug change, or a compounded product each behaves differently in your body, and the person who prescribed your medication is the one who can make the swap safely.
Whatever you do, don’t cold-stop
If there’s a single thing to take from this, it’s this. The riskiest response to a coverage letter is to just run out and stop. When you come off a GLP-1, appetite returns, and for most people the weight comes with it — trial data has people regaining roughly two-thirds of what they lost within a year of stopping. An unplanned gap is exactly the scenario most likely to cost you the progress you’re worried about losing.
So before your last covered refill runs out, get ahead of it. Book time with your prescriber while you still have medication in hand, not after you’ve run dry. Bring the specifics: your current medication and dose, how far you are from your goal, and what you can spend. That’s the conversation that turns a coverage change into a planned switch instead of an accidental cold-stop.
And keep tracking through the whole thing. A switch is precisely when your history earns its keep. If you move from injected Wegovy to an oral, or from a manufacturer product to a compounded one, your dose and your medication have changed — and the only way to see whether the new arrangement is holding your weight is to have the old baseline sitting right next to it. This is where Traqr is built to help: your dose log and weight history stay intact across a medication or dose switch, so the line on the chart doesn’t reset just because the label on the box did. If you’re coming off a compounder specifically, we’ve covered switching without losing your progress in more detail.
What to do this week
- Find your last-refill date. Read the letter or call your benefits administrator, and write the date down. Everything else keys off it.
- Get one cash-pay quote. Check the manufacturer’s direct-pay programme and your pharmacy’s self-pay price for your exact drug and dose, so “too expensive” is a real number, not a guess.
- Book your prescriber before you run out. Ask them to walk through cash-pay, oral, compounded, and maintenance-dose options against your goal and budget — while you still have medication in hand.
- If you’re on Medicare, check the Bridge. A separate $50-a-month GLP-1 copay programme started on 1 July 2026; we’ve broken down what the Medicare GLP-1 Bridge does and doesn’t cover.
- Keep logging. Record your weight and every dose right through the transition, so you can actually see whether the route you pick is holding.
A coverage change is a real hassle and it’s fine to be annoyed about it. But it doesn’t have to undo the work. The people who keep their progress through one of these switches are, almost always, the ones who planned the change with their prescriber and kept an eye on the numbers instead of guessing. You’ve done the hard part already. This is about not losing it in the handover.